EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty ...

BridgeBio Pharma said Finance Chief Brian Stephenson is leaving the company for personal reasons and will be replaced by Thomas Trimarch, who will continue holding the president role.

Brian Stephenson, Ph.D. will depart from the Company for personal reasons. Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s ...

We recently published a list of 10 Most Oversold Penny Stocks to Buy According to Analysts. In this article, we are going to ...

Sara Imhof, Ph.D., vice president of the focused initiatives team at the North Carolina Biotechnology Center, has been honored by a regional business publication for her inspiring work to lead North ...

As the Canadian market navigates a period of softened growth outlooks, diversification has emerged as a key strategy for investors seeking stability amidst volatility. Penny stocks, though often ...

Dayna is a seasoned executive with 20+ years of experience driving growth and talent strategies across multiple industries.

Apriori Bio has become the latest Flagship Pioneering-backed biotech to shed staff, cutting 15 workers to leave 21 still ...

Nick Smith is the President, Founder, and CEO of Sailes, a pioneering company that created market-leading AI software to ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...